HOTPAPERS

B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern, et al., “Genetic alterations during colorectal-tumor development,” The New England Journal of Medicine, 319,525-32, 1 September 1988. Bert Vogelstein (Molecular Genetics Laboratory, Johns Hopkins Oncology Center, Baltimore): “It is widely believed that cancer is the result of a series of genetic alterations. This paper is important because it lends substantial support to this belief with regard to one of the most common hu

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern, et al., “Genetic alterations during colorectal-tumor development,” The New England Journal of Medicine, 319,525-32, 1 September 1988. Bert Vogelstein (Molecular Genetics Laboratory, Johns Hopkins Oncology Center, Baltimore):

“It is widely believed that cancer is the result of a series of genetic alterations. This paper is important because it lends substantial support to this belief with regard to one of the most common human tumor types. The data in the paper suggest that colorectal neoplasia results from the mutational activation of an oncogne coupled with the loss of several genes that normally suppress tumorigenesis. The proposed model for colorectal cancers may also apply to other tumors in which such studies are more difficult to perform.

G.J. Dehmer, J.J. Pompa, E.K. van den Berg, E.J. Eichhorn, et al. “Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies